JP2009509970A - 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法 - Google Patents

酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法 Download PDF

Info

Publication number
JP2009509970A
JP2009509970A JP2008532483A JP2008532483A JP2009509970A JP 2009509970 A JP2009509970 A JP 2009509970A JP 2008532483 A JP2008532483 A JP 2008532483A JP 2008532483 A JP2008532483 A JP 2008532483A JP 2009509970 A JP2009509970 A JP 2009509970A
Authority
JP
Japan
Prior art keywords
antibody
protein
yeast
mutant
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509970A5 (enExample
Inventor
ユー ジェン，
ロバート ジェームス ルアレン，
Original Assignee
プロサイ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロサイ インコーポレイテッド filed Critical プロサイ インコーポレイテッド
Publication of JP2009509970A publication Critical patent/JP2009509970A/ja
Publication of JP2009509970A5 publication Critical patent/JP2009509970A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008532483A 2005-09-22 2006-09-22 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法 Pending JP2009509970A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71995205P 2005-09-22 2005-09-22
PCT/US2006/037302 WO2007035930A2 (en) 2005-09-22 2006-09-22 Glycosylated polypeptides produced in yeast mutants and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2009509970A true JP2009509970A (ja) 2009-03-12
JP2009509970A5 JP2009509970A5 (enExample) 2009-11-05

Family

ID=37889571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008532483A Pending JP2009509970A (ja) 2005-09-22 2006-09-22 酵母突然変異体において産生されるグリコシル化ポリペプチドおよびその使用方法

Country Status (6)

Country Link
US (1) US8202523B2 (enExample)
EP (1) EP1934605B1 (enExample)
JP (1) JP2009509970A (enExample)
CN (1) CN101313216A (enExample)
CA (1) CA2623197A1 (enExample)
WO (1) WO2007035930A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529426A (ja) * 2009-05-12 2012-11-22 ナショナル・ツィン・ファ・ユニヴァーシティ 抗ウイルス炭水化物結合モジュール組成物及び使用方法
JP2018511300A (ja) * 2015-01-16 2018-04-26 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗糖タンパク質抗体及びその使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080056688A (ko) * 2005-03-16 2008-06-23 유니버시티 오브 옥스퍼드 Ｈｉｖ－ｉ용 만노스 면역원
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
EP2134853B1 (en) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
CA2697091A1 (en) * 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
KR101498668B1 (ko) * 2008-12-04 2015-03-06 한국생명공학연구원 고분비성 단백질의 스크리닝 및 재조합 단백질의 생산을 위한 융합 파트너로서 그의 용도
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
JP2013511272A (ja) 2009-11-19 2013-04-04 オキシレイン ユーケー リミテッド 哺乳類様複合ｎ−グリカンを生成する酵母株
CN101914458B (zh) * 2010-02-09 2013-03-13 北京万特尔生物制药有限公司 白假丝酵母(甘露糖蛋白质复合体)菌毛株
SG189110A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd De-mannosylation of phosphorylated n-glycans
WO2012042386A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
US8986956B2 (en) 2010-11-04 2015-03-24 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
US8396871B2 (en) 2011-01-26 2013-03-12 DiscoverReady LLC Document classification and characterization
US10467252B1 (en) 2012-01-30 2019-11-05 DiscoverReady LLC Document classification and characterization using human judgment, tiered similarity analysis and language/concept analysis
US9667514B1 (en) 2012-01-30 2017-05-30 DiscoverReady LLC Electronic discovery system with statistical sampling
JP6194324B2 (ja) 2012-03-15 2017-09-06 オキシレイン ユーケー リミテッド ポンペ病の処置のための方法および材料
EP2929011A4 (en) * 2012-12-10 2016-05-25 Merck Sharp & Dohme MANIPULATED LOWER EUKARYOTIC HOSTES WITH LACKING GRR1 ACTIVITY FOR THE EXPRESSION OF RECOMBINANT PROTEINS
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2015082488A1 (en) * 2013-12-02 2015-06-11 Dsm Ip Assets B.V. Ice structuring protein
CN104725484B (zh) * 2013-12-19 2018-03-13 中国科学院微生物研究所 一种糖基化多肽及其制备方法和其应用
KR101750888B1 (ko) * 2014-09-23 2017-06-26 한국생명공학연구원 YlMpo1 과발현을 이용한 만노스인산화 증대 방법
CN113201054B (zh) * 2021-05-21 2022-07-05 华南农业大学 蛋白FoUPE1在调控香蕉枯萎病菌致病力中的应用
CN115160417B (zh) * 2022-06-24 2023-06-02 西南大学 盔形毕赤酵母Glyco_hydro类分泌蛋白及其应用
CN116590371B (zh) * 2023-07-13 2023-10-17 智享生物(苏州)有限公司 一种降低中华仓鼠卵巢细胞中抗体高甘露糖型的细胞培养方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033663A2 (en) * 2002-10-11 2004-04-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Carbohydrate-based synthetic vaccines for hiv
JP2008533175A (ja) * 2005-03-16 2008-08-21 ユニバーシティ・オブ・オックスフォード Ｈｉｖ−１のためのマンノース免疫原

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
DE3224788A1 (de) 1981-07-17 1983-02-03 South African Inventions Development Corp., Scientia, Pretoria,Transvaal Traegergebundenes immunogenes material
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
DE3885355T2 (de) 1987-05-29 1994-06-01 Shuzo Matsushita Monoklonale Antikörper.
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5266478A (en) 1987-05-29 1993-11-30 Tanox Biosystems, Inc. Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
US5763160A (en) 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5298419A (en) 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
US5445960A (en) 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5614612A (en) 1990-03-09 1997-03-25 Haigwood; Nancy L. Purified gp120 compositions retaining natural conformation
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5798251A (en) 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
US5914109A (en) 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
US5712373A (en) 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0554401A4 (en) 1990-10-26 1996-10-30 New York Health Res Inst Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5696238A (en) 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
AU668374B2 (en) 1991-12-10 1996-05-02 Dana-Farber Cancer Institute Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6103238A (en) 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
DE4301932A1 (de) 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh Hefewirtsstämme mit Defekten in der N-Glycosylierung
US6114143A (en) 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
US5843454A (en) 1993-05-07 1998-12-01 Akzo Nobel N.V. HIV immunogenic complexes
KR100372375B1 (ko) 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
ATE177843T1 (de) 1994-01-19 1999-04-15 Us Health Peptomere mit erhöhter immunogenizität
US5559010A (en) * 1994-04-04 1996-09-24 The Regents Of The University Of California Nutrient regulated gene expression systems
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
JPH11510047A (ja) 1995-07-21 1999-09-07 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ ＨＩＶ ｇｐ１２０の加水分解を触媒する組成物および方法
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP2767401B2 (ja) 1995-11-17 1998-06-18 工業技術院長 酵母のマンノース−１−リン酸転移酵素遺伝子およびこれを利用するマンノース−１−リン酸含有酸性糖鎖の製造方法
DE69636889T2 (de) 1995-11-30 2007-12-06 Nof Corp. Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
EP0854918A1 (en) 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
US6713069B1 (en) 1996-04-16 2004-03-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE60032370T2 (de) * 1999-08-19 2007-10-11 Kirin Beer K.K. Hefevarianten und verfahren zur herstellung von glykoprotein enthaltenden zuckerketten vom säugetiertyp
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
JP3905695B2 (ja) * 1999-08-31 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 分裂酵母の糖転移酵素遺伝子ｏｃｈ１
US6391567B1 (en) 2000-03-02 2002-05-21 New York University Identifying compounds inhibiting DC-sign facilitation of HIV into cells
ATE438722T1 (de) * 2000-05-17 2009-08-15 Mitsubishi Tanabe Pharma Corp Verfahren zur herstellung von proteinen unter reduktion von mannosephosphat in der zuckerkette und dadurch hergestelltes glykoprotein
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
PT1294910E (pt) 2000-06-30 2009-02-16 Vib Vzw Modificação da glicosilação de proteínas em pichia pastoris
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE420198T1 (de) * 2002-04-26 2009-01-15 Kirin Pharma Kk Methylotrophe hefe,die eine zuckerkette eines säugers herstellt
US7252933B2 (en) 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
US7250251B2 (en) 2002-09-09 2007-07-31 The J. David Gladstone Institutes Virion-based fusion assay
AU2003301804A1 (en) 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
EP1417965A1 (en) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
EP1569955A2 (en) * 2002-12-03 2005-09-07 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
CA2551484C (en) * 2003-12-24 2015-03-31 Glycofi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
US7728106B2 (en) * 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
CA2647632C (en) * 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EP2134853B1 (en) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033663A2 (en) * 2002-10-11 2004-04-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Carbohydrate-based synthetic vaccines for hiv
JP2008533175A (ja) * 2005-03-16 2008-08-21 ユニバーシティ・オブ・オックスフォード Ｈｉｖ−１のためのマンノース免疫原

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5008014818; Ｏｒｇａｎｉｃ　＆　Ｂｉｏｍｏｌｅｃｕｌａｒ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２，Ｎｏ．４, 2004, ｐ４８３-４８８ *
JPN5008014819; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２６８，Ｎｏ．３５, 1993, ｐ２６３３８-２６３４５ *
JPN6012002044; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７８，Ｎｏ．２３, 2004, ｐ１２９７５-１２９８６ *
JPN6012002047; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ Ｖｏｌ．１０２，Ｎｏ．３８, 20050920, ｐ１３３７２-１３３７７ *
JPN6012002050; Ｃｈｅｍｉｓｔｒｙ　＆　Ｂｉｏｌｏｇｙ Ｖｏｌ．１１，Ｎｏ．１, 2004, ｐ１２７-１３４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529426A (ja) * 2009-05-12 2012-11-22 ナショナル・ツィン・ファ・ユニヴァーシティ 抗ウイルス炭水化物結合モジュール組成物及び使用方法
JP2018511300A (ja) * 2015-01-16 2018-04-26 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗糖タンパク質抗体及びその使用

Also Published As

Publication number Publication date
WO2007035930A2 (en) 2007-03-29
CN101313216A (zh) 2008-11-26
US20080038286A1 (en) 2008-02-14
EP1934605A4 (en) 2008-12-17
EP1934605A2 (en) 2008-06-25
US8202523B2 (en) 2012-06-19
CA2623197A1 (en) 2007-03-29
EP1934605B1 (en) 2014-03-26
WO2007035930A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
EP1934605B1 (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
Luallen et al. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies
Kong et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity
CN102264896B (zh) 抗人流感病毒人型抗体
Xin et al. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis
US20230277643A1 (en) Mdr e. coli immunogen
US20100183669A1 (en) Mannose immunogens for HIV-1
NO300462B1 (no) Monoklonale antistoffer og peptider som kan anvendes til diagnose av HIV-infeksjoner
US5876716A (en) Method of using an antibody to the TN antigen for the inhibition of HIV infection
Zhao et al. Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus
JP2022520723A (ja) さまざまな真菌病原体に関連する感染症および疾患の治療および検出
CN106868025A (zh) 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
Liu et al. Altering the specificity of the antibody response to HIV gp120 with a glycoconjugate antigen
Luallen et al. Antibodies against Manα1, 2-Manα1, 2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains
US11655274B2 (en) Glycosylated YghJ polypeptides from enterotoxigenic Escherichia coli (ETEC)
JP7412689B2 (ja) 効率的な肝炎ウイルスの抗体誘導方法、抗体および検出系
HK1124917A (en) Glycosylated polypeptides produced in yeast mutants and methods of use thereof
EP0511967B1 (en) Medicaments and methods for treating acquired immune deficiency syndrome (aids) and aids-related complex (arc) employing anti-carbohydrate antibodies
WO2001030814A1 (fr) Complexe deglycosyle env/cd4 et son utilisation pour la vaccination contre le vih
US10596237B2 (en) Identification of pneumocystis antigens and uses thereof
CN101627050A (zh) 禽流感疫苗
JP2026512685A (ja) 組換え活性化関連分泌タンパク質
Wong et al. Potential use of a monoclonal antibody for the detection of Candida antigens in an experimental systemic candidiasis model
KR101149396B1 (ko) 사슴만성소모성질병의 변형프리온을 감별 및 검출할 수 있는 단클론항체, 이를 생산하는 융합세포주 및 그 용도
WO2021067741A1 (en) Glycopeptides for inducing an immune response and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130129